New York Biotechnology Association Announces Three Board Appointments
 
New York – January 15, 2008 – New York Biotechnology Association (NYBA), the voice of New York State’s biotechnology industry, today announced the appointment of Barbara Dalton, PhD, Barbara Wood, JD, and Jane Wasman, JD, to its Board of Directors.  
 
Dr. Nathan Tinker, NYBA Executive Director, said: “Biotechnology is a powerful economic driver for New York State and I am delighted that Barbara Wood, Barbara Dalton and Jane Wasman are bringing their skills and experience to our Board.  Their unsurpassed track records of professional achievement and intricate knowledge of the complex issues facing today’s biotechnology industry will further broaden the capabilities of our association as we work to enable a new platform for growth.”
 
Barbara Dalton, PhD, is Vice President for Venture Capital at Pfizer Inc. (New York, New York) and leads Pfizer Venture Investments with interests in a broad range of therapeutics from small molecules to biopharmaceuticals and vaccines as well specialty pharmaceuticals, diagnostics, drug delivery and health care technologies.  She is an experienced biotech investor who brings a wealth of experience to NYBA.
 
Barbara A. Wood is the Senior Vice President, General Counsel and Secretary at OSI Pharmaceuticals (Melville, NY). Before joining OSI in 2001, Ms. Wood was a partner in the Corporate Department of the New York office of Squadron Ellenoff Plesent & Sheinfeld LLP (now Hogan and Hartson LLP) where she began her legal career in 1987.
 
Jane Wasman has been Executive Vice President, General Counsel and Corporate Secretary for Acorda Therapeutics (Hawthorne, NY) since May 2004.  From 1995 to 2004, Ms. Wasman held various leadership positions at Schering-Plough Corporation, including Staff Vice President and Associate General Counsel responsible for legal support for US Pharmaceuticals operations, including sales, marketing and compliance; FDA regulatory matters; global research and development; and, corporate licensing and business development.  Previously, Ms. Wasman specialized in litigation at Fried, Frank, Harris, Shriver & Jacobson. She also served as Associate General Counsel to the US Senate Committee on Veteran's Affairs.

Media Contact:
Neil Vineberg
Vineberg Communications
631-371-0044
neil@vinebergcommunications.com